NCT01362504CompletedNot Applicable
Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit
Zekai Tahir Burak Women's Health Research and Education Hospital1 site in 1 country80 target enrollmentStarted: May 2011Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 80
- Locations
- 1
Study Overview
Brief Summary
The aim of this study was to clarify the prognostic value of serum pro-Adrenomedullin level in neonatal sepsis. Eighty term and preterm neonates with sepsis were enrolled in this study. Eighty healthy matched neonates served as a control group.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 24 Weeks to 42 Weeks (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Clinical sepsis and/or proven sepsis.
Exclusion Criteria
- •Acute kidney injury
- •Intracranial hemorrhage (Grade III and IV)
Investigators
Mehmet Yekta
Zekai Tahir Burak Maternity and Teaching Hospital
Zekai Tahir Burak Women's Health Research and Education Hospital
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Mid-Range Proadenomedullin for prognosis in patients undergoing Emergency Laparotomy for Intestinal PerforatioCTRI/2021/10/037434AIIMS Rishikesh
Completed
Not Applicable
Evaluation of Neonatal Adrenal Function by Serum Steroids Assaynewborn infantsJPRN-UMIN000014545Departmento of Pediatrics, National Hospital Organization(NHO) Saitama Hospital900
Unknown
Not Applicable
Prognostic Value of Proadrenomedullin in Intra-abdominal SepsisIntraabdominal InfectionsNCT03061500Instituto de Investigación Hospital Universitario La Paz100
Completed
Not Applicable
Adrenomedullin and Outcome in Severe Sepsis and Septic ShockSevere SepsisSeptic ShockNCT02393781Sphingotec GmbH596
Recruiting
Unknown
sing a blood test Adrenomedullin to predict disease severity andoutcome in patients with fever presenting to Emergency DepartmentCTRI/2023/07/054779Manipal Centre for Infectious Diseases (MACID)